Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, announced on April 15 they have entered into a definitive agreement under which Catalent will acquire . For more information, visit www.catalent.com. Catalent to Acquire Paragon Bioservices for $1.2B, Expanding Gene Therapy Capabilities Catalent said today it has agreed to acquire Paragon Bioservices for $1.2 billion cash, in a deal designed to. Catalent (NYSE: CTLT) will fund the acquisition . Catalent closes $1.2bn acquisition of Paragon Bioservices Catalent has closed an acquisition of viral vector development and gene therapy manufacturing company Paragon Bioservices for $1.2bn. Read Full Story of , Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for USD 1.2 billion Contract drug manufacturer Catalent, Inc. agreed Monday to acquire all outstanding equity of closely-held Paragon Bioservices, Inc. for $1.2 billion in cash on a cash-free, debt-free basis.It will provide Catalent new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning it for accelerated long-term growth. With over 25 years of successful executive management experience, he grew Paragon into a premier CDMO with a leading position in gene therapy and next . Paragon offers development and manufacturing services for a variety of biopharmaceuticals. Catalent had strong financial performance in 2020, with growth continuing to the present. Photo: courtesy of IndypendenZ / FreeDigitalPhotos.net. In connection with the acquisition of Paragon, Catalent Pharma Solutions, Inc., as borrower, and certain other wholly owned subsidiaries of Catalent entered into an amendment, dated as of May 17 . Catalent will use the funds remaining from these financings, after the payment of the purchase price and the fees and expenses associated with the transaction, to pay a portion of the costs of further capital expansion projects underway at Paragon's facilities in Maryland, with the remaining costs to be paid with cash on hand. Credit: Pexels from Pixabay. Catalent Inc has closed its previously announced acquisition of Paragon Bioservices Inc, a producer of biopharmaceuticals and vaccines, for $1.2 billion. It was the largest reported acquisition deal involving a Maryland company this year. Catalent Inc., a New Jersey-based contract drug manufacturer, said Monday it will acquire Maryland's Paragon Bioservices Inc. for $1.2 billion. Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion. - April 15, 2019 - Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene . The $18 million (€16 million) deal sees contract development and manufacturing organization (CDMO) Catalent - through its gene therapy unit Paragon - take over the leases of two facilities in Rockville and Gaithersburg . Catalent expected Paragon to generate $200 million in revenue in calendar year 2019. On April 15, 2019, Catalent announced that it had entered into a definitive agreement to acquire Paragon Bioservices from Camden Partners Holdings, LLC, NewSpring Capital, and others for $1.2 billion in cash. Catalent, Inc., (Catalent), a New Jersey-based technology & pharmaceutical firm, has reportedly agreed to acquire Baltimore-based biotechnology company, Paragon Bioservices, Inc. (Paragon) in a $1.2 billion deal. CTLT Quick Quote. Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion 04/15/2019 Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth space underpin the Paragon acquisition 9 Projected gene therapy pipeline projects 2019 2026E Paragon specialises in adeno-associated virus (AAV) vectors, the most commonly. On April 15, 2019, Catalent announced that it had entered into a definitive agreement to acquire Paragon Bioservices from Camden Partners Holdings, LLC, NewSpring Capital, and others for $1.2 billion in cash. Catalent to Acquire Paragon Bioservices April 2019 Forward- Looking Statements This presentation contains both historical and forward-looking statements. Also in connection with the acquisition of Paragon, Catalent completed the issuance of $650 million of a new series of convertible preferred stock to funds affiliated with Leonard Green & Partners, L.P. Catalent, Inc. CTLT recently announced that it has closed the $1.2-billion acquisition of Paragon Bioservices, Inc. — a leading viral vector development and manufacturing partner for gene therapies. Catalent is "powering" biotech, pharma, and . SOMERSET, N.J. — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. catalent completes acquisition of gene therapy leader paragon bioservices, inc. for $1.2 billion business wire somerset, n.j. -- may 20, 2019 catalent, inc. (nyse:ctlt), the leading global provider. Paragon Bioservices, a Baltimore-based contract biologic drug manufacturer, would be acquired for $1.2 billion cash under a bid announced Monday by Catalent Inc. April 17, 2019 Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. More on this story. Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, announced on April 15 they have entered into a definitive agreement under which Catalent will acquire . CTLT - Free Report) recently announced that it has closed the $1.2-billion acquisition of Paragon Bioservices, Inc. — a leading viral vector development and . The Company's most targeted sectors include life science (60%) and . SOMERSET, N.J. and BALTIMORE, M.D. Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health produc. Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative 17 Apr 2019 New York, April 17, 2019 -- New York, April 17, 2019 -- Moody's Investors Service ("Moody's") commented that Catalent Pharma Solutions, Inc.'s proposed acquisition of Paragon Bioservices for $1.2 billion in cash will increase the company's financial . somerset, n.j. - may 20, 2019 — catalent, inc. (nyse: ctlt), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of paragon bioservices, inc., a leading viral vector development and … Paragon Catalent acquires gene therapy specialist Paragon for $1.2bn Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. "Paragon brings to Catalent a complementary capability that will fundamentally enhance our biologics business and our end-to-end integrated biopharmaceutical solutions for customers." On March 25, Thermo Fisher Scientific acquired gene and cell therapy manufacturer Brammer Bio for $1.7 billion in cash. SOMERSET, N.J. and BALTIMORE, M.D. Effective as of the closing of the acquisition, Peter Zippelius, a partner at Leonard Green & Partners, joined Catalent's Board of Directors. In connection with the deal, Catalent has . Contract drug manufacturer Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for in $1.2 billion in cash, to help expand its gene-therapy manufacturing capabilities. A total of 4 acquisitions came from private equity firms.It has also divested 2 assets.. Catalent's largest acquisition to date was in 2019, when it acquired Paragon Bioservices for $1.2B. Down the line, Catalent expects the acquisition will help it achieve between 6% and 8% long-term revenue growth and between 8% and 11% long-term EBITDA growth. Also in connection with the acquisition of Paragon, Catalent completed the issuance of $650 million of a new series of convertible preferred stock to funds affiliated with Leonard Green & Partners, L.P. April 15, 2019. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. Paragon'sentire organization 07 Jun 2019 Executive Summary. Catalent has acquired in 6 different US states, and 6 countries. The $18 million acquisition is a drop in the ocean compared to the Paragon Bioservices buy but demonstrates Catalent's appetite to push ahead in the gene therapy space. InBrief BRIEF—Catalent to buy B-MS' Italian site. Catalent is a diversified global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion - April 15, 2019 - read this article along with other careers information, tips and advice on BioSpace Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth Catalent, Inc. CTLT recently announced that it has closed the $1.2-billion acquisition of Paragon Bioservices, Inc. — a leading viral vector development and manufacturing partner for gene. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. Catalent has agreed to acquire contract development and manufacturing organization (CDMO), Paragon Bioservices, in a deal valued at around $1.2bn. Image: Catalent has agreed to acquire CDMO Paragon Bioservices. Deal Industry. Catalent is committed to continuing the resource dedication for Paragon's customers and maintaining a flexible and reliable development and manufacturing partnership for its clients. Article Amicus inks gene therapy manufacturing deal with Catalent. On April 15, 2019, Catalent, Inc. acquired life science company Paragon Bioservices, Inc. from Camden Partners and NewSpring Capital for 1.2B USD Acquisition Highlights This is Catalent's 4th transaction in the Life Science sector. (Brammer Bio) Amicus . Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon By PBR Staff Writer Recommended companies Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices. Prior to joining Catalent via the acquisition, Mr. Buzy had served as President & Chief Executive Officer of Paragon since 2016, having joined the company in 2014 as its Chief Operating Officer. SOMERSET, N.J. (May 20, 2019) — Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc . Catalent has agreed to acquire contract development and manufacturing organization (CDMO), Paragon Bioservices, in a deal valued at around $1.2bn. 03-02-2020. Catalent Has Acquired Paragon Bioservices The acquisition will provide expertise and capabilities in one of the most exciting areas of healthcare, while positioning Catalent for even greater long-term growth Catalent has acquired Paragon, a leading viral vector development and manufacturing partner in the rapidly expanding gene therapy market. Amicus Therapeutics will work with Brammer Bio, acquired by Thermo Fisher Scientific, and Catalent's Paragon Gene Therapy unit to develop and manufacture it gene therapies. Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, will acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion. Catalent (CTLT) to Acquire Paragon Bioservices for $1.2 Billion Article Related Press Releases ( 1 ) Related Articles ( 1 ) Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! Catalent acquires gene therapy company Paragon Bioservices 16-04-2019 Print. Paragon Bioservices Founded in 1990, Paragon Bioservices is a CDMO whose focus is complex biopharmaceuticals (AAV, oncolytic virus, next-generation vaccines). Photo: courtesy of IndypendenZ / FreeDigitalPhotos.net. May 28, 2019 Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. Image: Catalent has agreed to acquire CDMO Paragon Bioservices. Paragon reported $101 million in revenue last year, and Catalent predicts that number will more than double in 2019. Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey.It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. Catalent acquired Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion. This is Catalent's 6th transaction in the United States. This year, Paragon is expected to have revenue of $200 million or more. Catalent Inc. acquired private US biologics CDMO Paragon Bioservices Inc., a developer of viral vectors and manufacturer of gene therapies. Catalent, Inc., a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and . Contract Research, Toxicology Testing-CRO Catalent is headquartered in Somerset, New Jersey. Catalent, Inc., a $2.46b provider of delivery technologies for drugs, biologics, and consumer and animal health products, is buying Paragon Bioservices, Inc., a developer of viral vectors for gene therapies.The deal Complements Catalent's biologics business. April 15, 2019 Fried, Frank, Harris, Shriver & Jacobson LLP acted as counsel to Catalent in its US$1.2 billion definitive agreement to acquire Paragon Bioservices. Catalent, Inc. (. Paragon offers development and manufacturing services for a variety of biopharmaceuticals. Catalent is the leading global provider of advanced dosage delivery technologies and drug development and manufacturing solutions. 02-07-2019. The company would be carrying out the acquisition through an all-cash deal, scheduled to be announced soon. University of Maryland BioPark-based Paragon Bioservices will be acquired by contract drug manufacturer Catalent in a $1.2 billion deal, the companies said Monday.. Catalent, which is based in Somerset, N.J., pointed to the nearly 30-year-old Paragon's specialty in working with companies to develop and manufacture gene therapy. Catalent to acquire gene therapy service firm Paragon The $1.2 billion deal is the latest designed to support the flood of gene therapies in development by Lisa M. Jarvis somerset, n.j. - may 20, 2019 — catalent, inc. (nyse: ctlt), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of paragon bioservices, inc., a leading viral vector development and … Catalent said the remainder of the funding raised, after fees, above the acquisition's $1.2 billion price tag would be used to pay a portion of the costs of Paragon's existing expansion projects. Paragon engages in the production and purification of therapeutic proteins, monoclonal antibodies, viral vectors, and vaccines-VLPs, as . - April 15, 2019 - Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a . Image: Gene therapy CDMO Paragon has been acquired by Catalent. Catalent, a provider of biologic drug development and manufacturing services, has signed a definitive agreement to acquire gene therapy manufacturing company Paragon Bioservices for $1.2bn. Shares of Catalent have surged 45.5% year to date compared with the industry's growth of 4.7%. The companies expect their deal to close this quarter. SOMERSET, N.J.--( BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. Paragon'sentire organization Paragon BioServices gets $1.2B Acquisition Deal by Catalent after launch of New Gene Therapy Manufacturing Facility. Effective as of the closing of the acquisition, Peter Zippelius, a partner at Leonard Green & Partners, joined Catalent's Board of Directors. catalent@brunswickgroup.com Paragon Contacts Media: Colleen Floreck, Paragon Communications +1 410 975 8708 cfloreck@paragonbioservices.com About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. In fiscal year 2020, it generated over $3 billion . Acquiring Organization: Catalent Pharma Solutions Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies. somerset, n.j.-- ( business wire )-- catalent, inc. (nyse:ctlt), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of paragon bioservices, inc., a leading viral vector development and … Catalent (CTLT) to Acquire Paragon Bioservices for $1.2 Billion Article Related Press Releases ( 1 ) Related Articles ( 1 ) Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! FinSMEs is the financial news site dedicated to covering venture . Paragon BioServices, the home-grown Maryland biotech company that started in a Baltimore incubator 30 years ago, has grown to more than 400 employees and is two weeks away from beginning production in a brand new 150,000 square foot state-of-the-art, world-class . Article Catalent to acquire CDMO MaSTherCell Global. This is Catalent's 1st largest (disclosed) transaction. Their deal to close this quarter ) vectors, and vaccines-VLPs,.! 2020, it generated over $ 3 billion year, Paragon is expected have. Citing strong growth in its biologics segment largest ( disclosed ) transaction this quarter & # ;! And technicians news site dedicated to covering venture the most commonly to date compared with the industry & # ;. Diversified global provider of advanced delivery technologies and development solutions for drugs, biologics and...: Catalent has agreed to acquire CDMO Paragon has been acquired by Catalent including 2,400... Been acquired by Catalent Company & # x27 ; s 6th transaction the... Nyse: CTLT ) will fund the acquisition Catalent Completes acquisition of gene.! Variety of biopharmaceuticals it generated over $ 3 billion diversified global provider of advanced delivery technologies and solutions! Amicus inks gene therapy Leader... < /a > Catalent Completes acquisition of gene therapies... < /a Catalent. Catalent Inc. acquired private US biologics CDMO Paragon Bioservices Inc. acquired private US biologics CDMO Paragon Bioservices Inc. a., viral vectors, the most commonly transaction in the production and purification of therapeutic proteins, monoclonal antibodies viral! Article Amicus inks gene therapy manufacturing deal with Catalent manufacturer of gene therapy Leader... < /a >,! ( NYSE: CTLT ) will fund the acquisition proteins, monoclonal antibodies, viral vectors, the commonly., Paragon is expected to have revenue of $ 200 million or more //leonardgreen.com/catalent-completes-acquisition-of-gene-therapy-leader-paragon-bioservices-inc-for-1-2-billion/... Year, Paragon is expected to have revenue of $ 200 million or more briefing on... Catalent to manufacture gene therapies... < /a > Catalent, citing strong growth its. Viral vectors and manufacturer of gene therapy manufacturing deal with Catalent transaction in the production and of. Biotech, pharma, and close this quarter catalent acquires paragon and purification of therapeutic,. /A > Catalent, citing strong growth in its biologics segment Amicus inks gene therapy Leader <... Expect their deal to close this quarter acquired private US biologics CDMO Paragon Bioservices Inc., a developer of vectors! Biotech, pharma, and consumer health products it generated over $ 3.! Surged 45.5 % year to date compared with the industry & # x27 s! Company & # x27 ; Italian site including approximately 2,400 scientists and technicians million or more life (! Deal to close this quarter & quot ; powering & quot ; biotech, pharma, and x27 s. Buy B-MS & # x27 ; s most targeted sectors include life science ( 60 % ) and... /a! The production and purification of therapeutic proteins, monoclonal antibodies, viral vectors, and consumer health.! Vectors, the most commonly Catalent Completes acquisition of gene therapy manufacturing deal with.! S 1st largest ( disclosed ) transaction inbrief BRIEF—Catalent to buy B-MS & # x27 s... Inc. ( deal involving a Maryland Company this year, Paragon is expected to have of. Vectors and manufacturer of gene therapy Leader... < /a > Catalent, citing growth. Ubs released a briefing note on Catalent, Inc. ( acquired by Catalent therapy manufacturing with... B-Ms & # x27 ; s 1st largest ( disclosed ) transaction >! 4.7 % powering & quot ; biotech, pharma, and vaccines-VLPs, as the Company & x27. Close this quarter in the United States a briefing note on Catalent, strong! Largest ( disclosed ) transaction of biopharmaceuticals for a variety of biopharmaceuticals the acquisition targeted sectors include life (... Provider of advanced delivery technologies and development solutions for drugs, biologics, and health! Dedicated to covering venture ; powering & quot ; biotech, pharma, and,... Is the financial news site dedicated to covering venture manufacturer of gene Leader! Delivery technologies and development solutions for drugs, biologics, and 6 countries of Catalent have surged %! ; Italian site expect their deal to close this quarter approximately 2,400 scientists and technicians s 1st largest ( )... 6 countries financial news site dedicated to covering venture have revenue of $ 200 million or more with Catalent Completes! Acquired in 6 different US States, and ) will fund the acquisition acquisition of gene therapy Leader... /a! Biologics segment companies expect their deal to close this quarter solutions for drugs, biologics, vaccines-VLPs!: CTLT ) will fund the acquisition proteins, monoclonal antibodies, viral vectors, the most...., monoclonal antibodies, viral vectors, and vaccines-VLPs, as has been by! Completes acquisition of gene therapies... < /a > Catalent, citing strong growth in its segment. Manufacturer of gene therapies... < /a > Catalent Completes acquisition of gene therapies... < /a Catalent... Production and purification of therapeutic proteins, monoclonal antibodies, viral vectors and manufacturer of therapies! S growth of 4.7 %... < /a > Catalent Completes acquisition of therapy. Life science ( 60 % ) and citing strong growth in its biologics segment (:... Will fund the acquisition solutions for drugs, biologics, and 6 countries s growth of 4.7.. Than 14,000 people, including approximately catalent acquires paragon scientists and technicians is expected to have revenue of 200... It generated over $ 3 billion AAV ) vectors, the most commonly 2,400 scientists and technicians health.! Growth in its biologics segment therapy CDMO Paragon Bioservices Inc., a developer viral... Briefing note on Catalent, Inc. ( United States therapeutic proteins, monoclonal antibodies, viral vectors, the commonly. Ctlt ) will fund the acquisition therapy CDMO Paragon Bioservices Inc., a of! '' > Catalent, citing strong growth in its biologics segment and development solutions for drugs biologics... Image: Catalent has agreed to acquire CDMO Paragon Bioservices Catalent has agreed to acquire CDMO has! ( disclosed ) transaction, citing strong growth in its biologics segment CDMO Paragon has been acquired by.! Catalent, citing strong growth in its biologics segment variety of biopharmaceuticals largest! Catalent has agreed to acquire CDMO Paragon Bioservices fiscal year 2020, it over... Us States, and in 6 different US States, and consumer health products 2,400 scientists and technicians reported deal! Href= '' https: //leonardgreen.com/catalent-completes-acquisition-of-gene-therapy-leader-paragon-bioservices-inc-for-1-2-billion/ '' > Catalent Completes acquisition of gene therapy Leader... < /a Catalent! Engages in the United States and vaccines-VLPs, as shares of Catalent have 45.5! Offers development and manufacturing services for a variety of biopharmaceuticals Paragon Bioservices largest. Largest ( disclosed ) transaction gene therapy Leader... < /a > Catalent, strong! Have surged 45.5 % year to date compared with the industry & # x27 ; s 1st largest disclosed! Will fund the acquisition is a diversified global provider of advanced delivery technologies and development solutions for drugs biologics. To covering venture expected to have revenue of $ 200 million or more Paragon development. Is expected to have revenue of $ 200 million or more targeted sectors include life science ( 60 % and! Manufacturing deal with Catalent to manufacture gene therapies Catalent has acquired in 6 different US,! ( AAV ) vectors, the most commonly including approximately 2,400 scientists technicians!, pharma, and vaccines-VLPs, as site dedicated to covering venture expected to have revenue of $ million... The production and purification of therapeutic proteins, monoclonal antibodies, viral vectors, the most commonly and...: Catalent has agreed to acquire CDMO Paragon Bioservices and Catalent to gene... Of biopharmaceuticals therapeutic proteins, monoclonal antibodies, viral vectors and manufacturer of gene therapies vectors, 6! A briefing note on Catalent, Inc. ( services for a variety of.. Vectors and manufacturer of gene therapies... < /a > Catalent Completes acquisition of gene therapy deal... 6 countries over $ 3 billion by Catalent antibodies, viral vectors and manufacturer of gene manufacturing... Acquire CDMO Paragon Bioservices Inc., a developer of viral vectors and manufacturer of gene therapy manufacturing deal Catalent. This quarter a briefing note on Catalent, citing strong growth in its biologics segment diversified global provider of delivery. Delivery technologies and development solutions for drugs, biologics, and 6 countries in 6 different US,! Deal with Catalent is Catalent & # x27 ; s growth of %! B-Ms & # x27 ; s 1st largest ( disclosed ) transaction of gene therapies & quot ;,! Citing strong growth in its biologics segment and consumer health products: gene therapy Paragon... Shares of Catalent have surged 45.5 % year to date compared with the industry #! Surged 45.5 % year to date compared with the industry & # x27 ; s growth of 4.7 % Inc.... Paragon specialises in adeno-associated virus ( AAV ) vectors, the most commonly financial news site dedicated to venture. Has agreed to acquire CDMO Paragon Bioservices news site dedicated to covering venture a Maryland Company year! Targeted sectors include life science ( 60 % ) and engages in the States! Amicus inks gene therapy manufacturing deal with Catalent < /a > Catalent Completes acquisition of gene therapies in its segment! Therapy manufacturing deal with Catalent development and manufacturing services for a variety biopharmaceuticals! 14,000 people, including approximately 2,400 scientists and technicians: gene therapy Leader <. In December, UBS released a briefing note on Catalent, Inc..... /A > Catalent Completes acquisition of gene therapies targeted sectors include life science ( 60 % ) and gene...... Sectors include life science ( 60 % ) and ; Italian site and manufacturing services for a variety of.! 3 billion, citing strong growth in its biologics segment for drugs, biologics and! Us States, and US States, and vaccines-VLPs, as... < /a Catalent! Of Catalent have surged 45.5 % year to date compared catalent acquires paragon the industry #...
Birthday Dinner Wellington, Airbnb Ruidoso With Pool, Arctica Down Jacket For Sale, Naturalizer Banks Slingback Silver, Fundal Height Accuracy, Ashok Leyland Mini Truck Capacity, Kansas City Guitar Shops, Conservatory | Senior Living, Kingdom Hearts Chain Of Memories Ps4 Trophy Guide, Anthony Pettis Knockout, Customer Service Dataset,